BioSpecifics Technologies Corp. Announces Data from Multiple Studies of XIAFLEX for Treatment of Dupuytren's Contracture

   BioSpecifics Technologies Corp. Announces Data from Multiple Studies of
XIAFLEX for Treatment of Dupuytren's Contracture Presented at American Society
                         for Surgery of the Hand 2013

- Clinical Papers Presented on Four-Year Data from CORDLESS Recurrence Study
and Three-Year Safety Data -

- Positive Data Reported on Use of Local Anesthesia in Dupuytren's Contracture
Procedures -

PR Newswire

LYNBROOK, N.Y., Oct. 7, 2013

LYNBROOK, N.Y., Oct. 7, 2013 /PRNewswire/ --BioSpecifics Technologies Corp.
(NASDAQ: BSTC), a biopharmaceutical company developing first in class
collagenase-based products marketed as XIAFLEX^® in the U.S. and XIAPEX^® in
the EU, announced today that data from multiple trials evaluating the use of
XIAFLEX ("collagenase clostridium histolyticum" or "CCH") in adult patients
with Dupuytren's contracture with a palpable cord were presented by
BioSpecifics' partner Auxilium Pharmaceuticals, Inc. (Auxilium) at the 68th
Annual Meeting of the American Society for Surgery of the Hand ("ASSH") that
took place in San Francisco, California, on October 3 – 5, 2013.

"We believe the data presented at ASSH on XIAFLEX further validates that
XIAFLEX is a safe and efficacious treatment for adult patients with
Dupuytren's contracture and it remains the only non-surgical option available
today," commented Thomas L. Wegman, President of BioSpecifics. "We continue to
support Auxilium in their commercialization efforts for this product and look
forward to potentially adding a second FDA-approved indication by the end of
the year for Peyronie's disease."

Auxilium presented results at ASSH from Year 4 of the Collagenase Optimal
Reduction of Dupuytren's - Long-term Evaluation of Success Study ("CORDLESS").
CORDLESS is a five-year observational study designed to assess the rates of
recurrence following treatment with XIAFLEX, as well as long-term safety and
progression of disease in patients from earlier Auxilium studies. These data
indicated that 57.9 percent of patients previously successfully treated with
XIAFLEX did not experience disease recurrence based on the study's definition
of recurrence, which is a 20 degree change of contracture with a palpable
cord, or the joint undergoing medical or surgical intervention. Of the 623
joints assessed, only 12.8 percent of those joints received medical or
surgical intervention through Year 4 and of these patients, most were
retreated with XIAFLEX. The data also reveal no new long-term adverse events.
Of the 86 serious AEs reported through four years of follow-up, only one was
considered related to XIAFLEX (decrease in ring finger circumference due to
Dupuytren's contracture resolution).

Additional data highlights from the CORDLESS study can be found in Auxilium's
press release issued today.

CORDLESS study authors also presented an update on XIAFLEX safety data
following three years of post-approval use and determined that after an
estimated 49,078 XIAFLEX injections were administered to approximately 36,500
adult patients in the U.S. for the treatment of Dupuytren's contracture with a
palpable cord, there was no clinically meaningful change in the nature of
events reported relative to the one year post-marketing safety profile.[1]
Adverse events were most commonly localized, non-serious reactions to XIAFLEX
injections, including skin tears, contusion (bruising), peripheral edema
(swelling), extremity pain and injection site reactions.

Based on data from a previous Phase 3b trial, Stephen Coleman and his
colleagues at the Brisbane Hand and Upper Limb Clinic provided an analysis on
the use of local anesthesia (LA) prior to Dupuytren's contracture correction
procedures. Sixty adult patients with Dupuytren's contracture with a palpable
cord were enrolled and treated, with 120 treated joints (75
metacarpophalangeal (MP), 45 proximal interphalangeal (PIP). Overall 27/60
patients received LA prior to finger extension; the remaining patients had
finger extension procedures without LA. As presented in the poster [2], it was
determined that the use of LA prior to a finger extension procedure following
XIAFLEX injection led to greater improvement in the correction of contracture
(82.6% vs. 69.8%), despite the patients having more severe contracture (total
fixed flexion contracture (FFC) 90.3˚ vs 84.2˚). It was also demonstrated that
PIP joints tended to show a better response than MP joints. Percent changes
from baseline including FFC for PIP joints were 74.7% with LA and 59.7%
without while MP joints were 77.8% and 74.4%, respectively. LA was not
utilized in earlier Phase 3 trials but may allow physicians to use more force
during the finger extension procedure without significant added pain to the

[1] Peimer CA et al. Nonsurgical treatment of Dupuytren's contracture: 1-year
US post-marketing safety data for collagenase clostridium histolyticum. Hand.

[2] Coleman S et al. Use of Local Anesthesia Prior to Finger Extension
Following Injection of Collagenase Clostridium Histolyticum for Dupuytren's
Contracture. Poster presented at ASSH 2013, the 68th Annual Meeting of the
American Society for Surgery of the Hand. 2013 Oct 3-5; San Francisco CA.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for twelve clinical indications to date.
Injectable collagenase is currently marketed as XIAFLEX^® (collagenase
clostridium histolyticum (CCH)) in the U.S. for the treatment of adult
Dupuytren's contracture patients with a palpable cord in the palm by
BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) and marketed
in Europe and approved in Canada. Swedish Orphan Biovitrum AB has marketing
rights for XIAPEX^® (the EU tradename for CCH) for the treatment of
Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African
countries. Asahi Kasei Pharma Corporation has development and
commercialization rights for XIAFLEX for the treatment of Dupuytren's
contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals Ltd.
has development and commercialization rights for XIAFLEX for these two
indications in Canada, Mexico, Brazil and Australia. CCH is in clinical
development for the treatment of several additional promising indications.
Under the Prescription Drug User Fee Act (PDUFA), the FDA has set an action
date for XIAFLEX for Peyronie's disease of December 6, 2013.Auxilium is
testing CCH for frozen shoulder syndrome and cellulite and expects to initiate
a Phase II trial of CCH for cellulite and next stage trials of CCH for frozen
shoulder syndrome in the fourth quarter of 2013. BioSpecifics is currently
managing the development of CCH for the treatment of human and canine lipomas,
both of which are in Phase II trials, and expects to report top-line data from
these trials by the end of 2013. For more information, please visit

Forward-Looking Statements

This release includes "forward-looking statements" within the meaning of, and
made pursuant to the safe harbor provisions of, the Private Securities
Litigation Reform Act of 1995. All statements other than statements of
historical fact are "forward-looking statements". The forward-looking
statements include statements concerning, among other things, the timing of
the review and potential approval by the FDA of XIAFLEX as a treatment for
Peyronie's disease; the extent to which additional indications are promising;
the timing for Auxilium to initiate a phase II trial of CCH as a treatment for
cellulite and next stage trials of CCH as a treatment for frozen shoulder; and
the timing of reporting top-line data from BioSpecifics' trials of CCH for the
treatment of human lipoma and canine lipoma. In some cases, you can identify
these statements by forward-looking words such as "believe," "expect,"
"anticipate," "plan," "estimate," "likely," "may," "will," "could,"
"continue," "project," "predict," "goal," the negative or plural of these
words, and other similar expressions. These forward-looking statements are our
predictions based on our current expectations and our projections about future
events. There are a number of important factors that could cause our actual
results to differ materially from those indicated by such forward-looking
statements, including the ability of Auxilium and its partners to achieve
their respective objectives for XIAFLEX in their applicable territories; the
uncertainties inherent in the initiation of future clinical trials; Auxilium
or any of its partners modifying their respective objectives and/or allocating
resources other than to XIAFLEX; the potential market for XIAFLEX in a given
indication being smaller than anticipated; the potential of XIAFLEX to be used
in additional indications and the initiation, timing and outcome of clinical
trials of XIAFLEX for additional indications; the timing of regulatory filings
and action; the receipt of any applicable milestone payments from Auxilium;
and other risk factors identified in our Annual Report on Form 10-K for the
year ended December 31, 2012, our Quarterly Reports on Form 10-Q for the
quarters ended March 31, 2013 and June 30, 2013, and our Current Reports on
Form 8-K filed with the SEC. All forward-looking statements included in this
release are made as of the date hereof, and we assume no obligation to update
these forward-looking statements.

SOURCE BioSpecifics Technologies Corp.

Contact: BioSpecifics Technologies Corp., Thomas L. Wegman, President, (516)
Press spacebar to pause and continue. Press esc to stop.